Altered monoaminergic transporter binding in hepatitis C related cerebral dysfunction: A neuroimmunologial condition?

Gut

Volumn 55, Issue 11, 2006, Pages 1535-1537

  Forton, D M ^a  

^a ST GEORGE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; CYTOKINE RECEPTOR; GAMMA INTERFERON; INDOLEAMINE 2,3 DIOXYGENASE; INTERLEUKIN 2; SEROTONIN UPTAKE INHIBITOR;

ANXIETY; BRAIN DYSFUNCTION; CENTRAL NERVOUS SYSTEM; DEPRESSION; DISEASE ASSOCIATION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; NEUROIMMUNOLOGY; NEUROTRANSMISSION; NOTE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL STATUS; SUBSTANCE ABUSE; VIRUS HEPATITIS;

BRAIN; COGNITION DISORDERS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; HEPATITIS C, CHRONIC; HUMANS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 33750284202     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2006.100081     Document Type: Note

References (30)

1. Poynard T, Cacoub P, Ratziu V, et al. Fatigue in patients with chronic hepatitis C. J Viral Hepat 2002;9:295-303.
2. Kramer L, Hofer H, Bauer E, et al. Relative impact of fatigue and subclinical cognitive brain dysfunction on health-related quality of life in chronic hepatitis C infection. AIDS 2005;19(suppl 3):S85-92.
3. Goh J, Coughlan B, Quinn J, et al. Fatigue does not correlate with the degree of hepatitis or the presence of autoimmune disorders in chronic hepatitis C infection. Eur J Gastroenterol Hepatol 1999;11:833-8.
4. Wessely S, Pariante C. Fatigue, depression and chronic hepatitis C infection. Psychol Med 2002;32:1-10.
5. Barrett S, Goh J, Coughlan B, et al. The natural course of hepatitis C virus infection after 22 years in a unique homogenous cohort: spontaneous viral clearance and chronic HCV infection. Gut 2001;49:423-30.
6. Rodger AJ, Jolley D, Thompson SC, et al. The impact of diagnosis of hepatitis C virus on quality of life. Hepatology 1999;30:1299-301.
7. Weissenborn K, Ennen JC, Bokemeyer M, et al. Monoaminergic neurotransmission is altered in hepatitis C virus infected patients with chronic fatigue and cognitive impairment. Gut 2006;55:1624-30.
8. Forton DM, Allsop JM, Main J, et al. Evidence for a cerebral effect of the hepatitis C virus. Lancet 2001;358:38-9.
9. Forton DM, Thomas HC, Murphy CA, et al. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology 2002;35:433-9.
10. Weissenbom K, Krause J, Bokemeyer M, et al. Hepatitis C virus infection affects the brain-evidence from psychometric studies and magnetic resonance spectroscopy. J Hepatol 2004;41:845-51.
11. McAndrews MP, Farcnik K, Carlen P, et al. Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors. Hepatology 2005;41:801-8.
12. Hilsabeck RC, Perry W, Hassanein TI. Neuropsychological impairment in patients with chronic hepatitis C. Hepatology 2002;35:440-6.
13. Meyerhoff DJ, Bloomer C, Cardenas V, et al. Elevated subcortical choline metabolites in cognitively and clinically asymptomatic HIV+ patients. Neurology 1999;52:995-1003.
14. Radkowski M, Wilkinson J, Nowicki M, et al. Search for hepatitis C virus negative-strand RNA sequences and analysis of viral sequences in the central nervous system: evidence of replication. J Virol 2002;76:600-8.
15. Forton DM, Karayiannis P, Mahmud N, et al. Identification of unique hepatitis C virus quasispecies in the central nervous system and comparative analysis of internal translational efficiency of brain, liver, and serum variants. J Virol 2004;78:5170-83.
16. Piche T, Vanbiervliet G, Cherikh F, et al. Effect of ondansetron, a 5-HT3 receptor antagonist, on fatigue in chronic hepatitis C: a randomised, double blind, placebo controlled study. Gut 2005;54:1169-73.
17. Capuron L, Neurauter G, Musselman DL, et al. Interferon-alpha-induced changes in tryptophan metabolism. Relationship to depression and paroxetine treatment. Biol Psychiatry 2003;54:906-14.
18. Kraus MR, Schafer A, Faller H, et al. Paroxetine for the treatment of interferon-alpha-induced depression in chronic hepatitis C. Aliment Pharmacol Ther 2002;16:1091-9.
19. Wichers MC, Maes M. The psychoneuroimmunopathophysiology of cytokine-induced depression in humans. Int J Neuropsychopharmacol 2002;5:375-88.
20. Hayley S, Merali Z, Anisman H. Stress and cytokine-elicited neuroendocrine and neurotransmitter sensitization: implications For depressive illness. Stress 2003;6:19-32.
21. Bluthe RM, Michaud B, Kelley KW, et al. Vagotomy blocks behavioural effects of interleukin-1 injected via the intraperitoneal route but not via other systemic routes. Neuroreport 1996;7:2823-7.
22. Nguyen KT, Deak T, Owens SM, et al. Exposure to acute stress induces brain interleukin-1 beta protein in the rat. J Neurosci 1998;18:2239-40.
23. Ramamoorthy S, Ramamoorthy JD, Prasad PD, et al. Regulation of the human serotonin transporter by interleukin-1 beta. Biochem Biophys Res Commun 1995;216:560-7.
24. Morikawa O, Sakai N, Obara H, et al. Effects of interferon-[alpha], interferon-[gamma] and cAMP on the transcriptional regulation of the serotonin transporter. Eur J Pharmacol 1998;349:317-24.
25. Kamata M, Higuchi H, Yoshimoto M, et al. Effect of single intracerebroventricular injection of [alpha]-interferon on monoamine concentrations in the rat brain. Eur Neuropsychopharmacol 2000;10:129-32.
26. Bonaccorso SM, Marino VM, Puzella AM, et al. Increased depressive ratings in patients with hepatitis C receiving interferon-[alpha]-based immunotherapy are related to interferon-[alpha]-induced changes in the serotonergic system. J Clin Psychopharmacol 2002;22:86-90.
27. Wichers MC, Maes M. The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression. J Psychiatry Neurosci 2004;29:11-17.
28. Schrocksnadel K, Wirleitner B, Winkler C, et al. Monitoring tryptophan metabolism in chronic immune activation. Clin Chim Acta 2006;364:82-90.
29. Fuchs D, Moller AA, Reibnegger G, et al. Increased endogenous interferon-gamma and neopterin correlate with increased degradation of tryptophan in human immunodeficiency virus type 1 infection. Immunol Lett 1991;28:207-11.
30. Fuchs D, Moller AA, Reibnegger G, et al. Decreased serum tryptophan in patients with HIV-1 infection correlates with increased serum neopterin and with neurologic/psychiatric symptoms. J Acquir Immune Defic Syndr 1990;3:873-6.